Company News

2025/4/15-On April 15th, 2025, Polaris Group-KY (6550) held a groundbreaking ceremony for the new plant with the expansion of 6 production lines at Zhunan. The attending guests and the ones sending their congratulations include Hsinchu Science Park Bureau, Longtai Construction, Hua Nan Bank, Taiwan Cooperative Bank, Shanghai Commercial & Savings Bank, Anxo Pharmaceutical, and many representatives from different industries. Chairman and CEO of Polaris Group Dr. Steve Hsu gave a ceremonial speech, mentioning that Polaris plans to invest a total of approximately NT$8 billion in phases to expand production capacity over the next five years (2025-2029), with the goal of reaching an annual output value of NT$100 billion with the dual engines after the full expansion with loaded capacity. The dual engine model includes (1) ADI-PEG20 (trade name ADZODI) for (a) malignant pleural mesothelioma (lung mesothelioma, MPM), (b) glioblastoma (brain cancer, GBM), leiomyosarcoma (LMS), acute myeloid leukemia (AML), and other indications (2) GLP-1 generics for diabetes, weight loss, and other indications.

2025/4/14-Polaris Group-KY (6550) announces today its US California subsidiary Polaris Pharmaceuticals Inc. (PPI) signed a distribution agreement with Er-Kim Pharmaceuticals, an international company specializing in the commercialization of novel therapies for pharmaceutical and biopharmaceutical companies. Polaris appointed Er-Kim as the exclusive partner to commercialize Pegargiminase (ADZODI) across 36 markets in the EMEA region (Central & Eastern Europe, Eurasia, North Africa and Mediterranean regions).

2025/4/14-Polaris Group-KY (6550) announces today its US California subsidiary Polaris Pharmaceuticals Inc. (PPI) signed an exclusive licensing agreement with Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group, a listed company in Saudi Arabia) to introduce ADI-PEG20 (ADZODI), a novel treatment for Malignant Pleural Mesothelioma (MPM), to the 7 markets in Saudi Arabia and the GCC region. This partnership is set to improve the treatment landscape by delivering innovative therapeutic solution aimed at improving patient outcomes across the region.

2024/12/10-Polaris Group-KY announced that it has successfully completed its Year 2024 capital injection with fully raising NT$1,176 million and scheduling to list the newly issued shares on December 11, 2024. This successful capital injection received strong support from domestic and international investors, reflecting the market’s confidence in the company’s development prospects.